Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Changes Name to Oscient

NEW YORK, April 13 (GenomeWeb News) - Genome Therapeutics said today that it has changed its name to Oscient Pharmaceuticals "to better reflect its focus on drug development and commercialization" following its merger with Genesoft Pharmaceuticals in February.

Genome Therapeutics shareholders approved the change to Oscient (pronounced AWE-see-ent) today at the company's annual meeting in Boston. The name change will take effect immediately and the company's stock will continue to trade on Nasdaq under the ticker symbol "GENE."

Oscient's corporate headquarters will remain in Waltham, Mass., with west coast offices in South San Francisco.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.